Roche MS drug reduces brain lesions, meeting goals of phase 2 trial
yuelan Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said its oral drug fenebrutinib met the main and secondary goals of a phase 2 trial ...
yuelan Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said its oral drug fenebrutinib met the main and secondary goals of a phase 2 trial ...
Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.